What is LGVN's current stock price?

LGVN (Longeveron Inc.) is currently trading at $0.84 with a market cap of $18.2M.

What sector is Longeveron Inc. in?

Longeveron Inc. (LGVN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is LGVN a good stock to buy?

Analysts have a Buy consensus on LGVN with a price target of $10.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

LGVN Longeveron Inc.

Healthcare

$0.84+0.00%OpenMarket Cap: $18.2M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.27

P/S

14.69

EV/EBITDA

-0.13

DCF Value

$-1.37

FCF Yield

-104.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

65.1%

Operating Margin

-1881.7%

Net Margin

-1844.5%

ROE

-202.4%

ROA

-105.7%

ROIC

-130.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$398.0K	$-4.7M	$—
Q4 null	$365.0K	$-5.4M	$—
FY null	$1.2M	$-22.7M	$—
Q3 null	$137.0K	$-7.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

1 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

Maxim GroupHold

2026-05-11

HC Wainwright & Co.Buy

2026-05-04

Roth CapitalBuy

2025-08-15

Trading Activity

Insider Trades

View All

Willard Stephen Hofficer: Chief Executive Officer

SellTue May 05

Locklear Lisaofficer: Chief Financial Officer

SellTue May 05

Lehr Paul Tofficer: General Counsel, Secretary

SellTue May 05

Blass Devinofficer: CTO & SVP of CMC

SellTue May 05

Agafonova Nataliyaofficer: Chief Medical Officer

SellTue May 05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.32

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Peers